Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Go back to Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 103.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $103.66 | 52 Week High | $118.49 | |||
| Open | $103.66 | 52 Week Low | $55.00 | |||
| Day High | $103.66 | P/E | N/A | |||
| Day Low | $103.66 | EPS | $-0.56 | |||
| Volume | 873 | |||||
